Newland Pharmaceutical Co (SZSE:301277) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Newland Pharmaceutical Co Debt-to-Equity?

Newland Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1.9 Mil. Newland Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.5 Mil. Newland Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,504.7 Mil. Newland Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Newland Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

During the past 6 years, the highest Debt-to-Equity Ratio of Newland Pharmaceutical Co was 0.36. The lowest was 0.00. And the median was 0.15.

SZSE:301277's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Newland Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Newland Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newland Pharmaceutical Co Debt-to-Equity Chart

Newland Pharmaceutical Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.36

0.35

0.31

Newland Pharmaceutical Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Newland Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Newland Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newland Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newland Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Newland Pharmaceutical Co's Debt-to-Equity falls into.

Newland Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Newland Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.991	+	0.727)	/	1448.017
	=	0.00

Newland Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.873	+	0.496)	/	1504.675
	=	0.00

Newland Pharmaceutical Co (SZSE:301277) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Newland Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Newland Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Newland Pharmaceutical Co (SZSE:301277) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newland Pharmaceutical Co Ltd (SZSE:301277) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

East side of the south section of Weiwu Road, Henan Province, Changge, CHN, 461500

Website

http://www.newlandpharma.com

Newland Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chiral pharmaceutical intermediates.

Newland Pharmaceutical Co (SZSE:301277) Headlines

No Headlines